Biologics based on the structure of fibroblast growth factor (FGF) 19 and 21 show strong beneficial effects in the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD), including compensated cirrhosis. Here, FGF19 is linked to metabolic dysfunction-associated steatotic liver disease.